ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Blood Test Discussion
Calculate Free Testosterone with TruT by FPT
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 239467" data-attributes="member: 13851"><p><strong>Phase IIB: Development of TruT Algorithm for Commercialization in Androgen Disorders (2022)</strong></p><p>[URL unfurl="true"]https://reporter.nih.gov/search/15ECC90D4A8BC3D57598B8961CAA4A01A2FFCEB861BF/project-details/10603887[/URL]</p><p></p><p>[ATTACH=full]26982[/ATTACH]</p><p></p><p></p><p><strong><em>TruTTM (v2.0) algorithm</em></strong></p><p><strong></strong></p><p><strong>ABSTRACT</strong></p><p><strong></strong></p><p><strong>Background: </strong><em>Measurement of free testosterone (T) concentrations is indicated in the diagnosis of androgen disorders, including hypogonadism in men; hirsutism, polycystic ovary syndrome (PCOS), and androgenic alopecia in women; pubertal disorders in boys and management of gender-affirming hormone therapies for transgender and gender diverse (TGD) persons.<strong> This Phase IIB proposal aims to continue the development of the TruTTM algorithm by validating it in common conditions characterized by altered estradiol (E2), T, and SHBG concentrations and incorporating the interaction of E2 with T for wider commercial adoption in women in whom E2 levels vary greatly across the menstrual cycle and in TGD population.</strong></em></p><p></p><p><strong>Approach: </strong><em><strong>This application follows the FDA’s published “<u>Guidance for Industry: Bioanalytical Method Validation</u>”.</strong> </em></p><p></p><p><strong><em>The essential parameters to determine the acceptability of a bioanalytical method include its technical performance (accuracy, precision, sensitivity, selectivity, stability, and matrix effects). </em></strong></p><p><strong><em></em></strong></p><p><strong><em>Reference ranges should be determined in appropriate human samples. </em></strong></p><p><strong><em></em></strong></p><p><strong><em>The analytical method should be validated for the intended use (e.g., determination in conditions of intended use, such as persons with altered E2 and T levels, women with PCOS, TGD persons, etc.). </em></strong></p><p><strong><em></em></strong></p><p><strong><em>In studies through the Phase II, we demonstrated that the method has superior performance characteristics and extended the validation of TruTTM algorithm in conditions characterized by altered SHBG concentrations. </em></strong></p><p><strong><em></em></strong></p><p><strong><em>*In the proposed Phase IIB studies, we will generate the v2.0 of TruTTM algorithm by incorporating the dynamics of the E2 induced perturbation in free T levels, validate it in men, women, and TGD populations (<u>Aim 1</u>) and deploy HIPAA-compliant, secure integration of the algorithm into electronic medical records (EMR) workflow </em></strong></p><p><strong><em></em></strong></p><p><strong><em>*(<u>Aim 2</u>). <u>Future Directions and Commercialization potential</u>: The phase IIB program will enable the pilot commercial deployment of a HIPAA-compliant (FDA registered) platform for commercializing the TruTTM (v2.0) algorithm embedded into electronic medical record (EMR) for wider clinical adoption.</em></strong></p><p><strong><em></em></strong></p><p><strong><em>These studies will improve clinical care and <u>advance our fundamental understanding of dynamic regulation of T bioavailability</u> in diverse populations including unrepresented sexual and gender minorities.</em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Phase IIB: Development of TruT Algorithm for Commercialization in Androgen Disorders (2022)</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Project Start Date: <em>15 September 2014</em></strong></p><p><strong></strong></p><p><strong>Project End Date: <em>31-August-2024</em></strong></p><p><strong>[ATTACH=full]26983[/ATTACH]</strong></p><p><strong>[ATTACH=full]26984[/ATTACH]</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Phase II: Research and Commercialization of TruT Algorithm for Free Testosterone (2018)</strong></p><p>[URL unfurl="true"]https://reporter.nih.gov/search/15ECC90D4A8BC3D57598B8961CAA4A01A2FFCEB861BF/project-details/9564777[/URL]</p><p></p><p></p><p><strong>Phase II: Research and Commercialization of TruT Algorithm for Free Testosterone (2017)</strong></p><p>[URL unfurl="true"]https://reporter.nih.gov/search/15ECC90D4A8BC3D57598B8961CAA4A01A2FFCEB861BF/project-details/9466689[/URL]</p><p></p><p></p><p><strong>Novel Algorithm for Free Testosterone Determination (2014)</strong></p><p>[URL unfurl="true"]https://reporter.nih.gov/search/15ECC90D4A8BC3D57598B8961CAA4A01A2FFCEB861BF/project-details/8647313[/URL]</p><p></p><p></p><p></p><p></p><p>[URL unfurl="true"]https://www.sciencedirect.com/science/article/abs/pii/S030372071400272X?via%3Dihub[/URL]</p><p></p><p>[URL unfurl="true"]https://academic.oup.com/edrv/article/38/4/302/3897170[/URL]</p><p></p><p>[URL unfurl="true"]https://www.excelmale.com/forum/threads/allosterically-coupled-multi-site-binding-of-t-to-human-serum-albumin.22102/[/URL]</p><p></p><p>[URL unfurl="true"]https://www.excelmale.com/forum/threads/the-dynamics-of-allosteric-binding-of-estradiol-to-shbg.23268/#post-199558[/URL]</p></blockquote><p></p>
[QUOTE="madman, post: 239467, member: 13851"] [B]Phase IIB: Development of TruT Algorithm for Commercialization in Androgen Disorders (2022)[/B] [URL unfurl="true"]https://reporter.nih.gov/search/15ECC90D4A8BC3D57598B8961CAA4A01A2FFCEB861BF/project-details/10603887[/URL] [ATTACH type="full" alt="Screenshot (18627).png"]26982[/ATTACH] [B][I]TruTTM (v2.0) algorithm[/I] ABSTRACT Background: [/B][I]Measurement of free testosterone (T) concentrations is indicated in the diagnosis of androgen disorders, including hypogonadism in men; hirsutism, polycystic ovary syndrome (PCOS), and androgenic alopecia in women; pubertal disorders in boys and management of gender-affirming hormone therapies for transgender and gender diverse (TGD) persons.[B] This Phase IIB proposal aims to continue the development of the TruTTM algorithm by validating it in common conditions characterized by altered estradiol (E2), T, and SHBG concentrations and incorporating the interaction of E2 with T for wider commercial adoption in women in whom E2 levels vary greatly across the menstrual cycle and in TGD population.[/B][/I] [B]Approach: [/B][I][B]This application follows the FDA’s published “[U]Guidance for Industry: Bioanalytical Method Validation[/U]”.[/B] [/I] [B][I]The essential parameters to determine the acceptability of a bioanalytical method include its technical performance (accuracy, precision, sensitivity, selectivity, stability, and matrix effects). Reference ranges should be determined in appropriate human samples. The analytical method should be validated for the intended use (e.g., determination in conditions of intended use, such as persons with altered E2 and T levels, women with PCOS, TGD persons, etc.). In studies through the Phase II, we demonstrated that the method has superior performance characteristics and extended the validation of TruTTM algorithm in conditions characterized by altered SHBG concentrations. *In the proposed Phase IIB studies, we will generate the v2.0 of TruTTM algorithm by incorporating the dynamics of the E2 induced perturbation in free T levels, validate it in men, women, and TGD populations ([U]Aim 1[/U]) and deploy HIPAA-compliant, secure integration of the algorithm into electronic medical records (EMR) workflow *([U]Aim 2[/U]). [U]Future Directions and Commercialization potential[/U]: The phase IIB program will enable the pilot commercial deployment of a HIPAA-compliant (FDA registered) platform for commercializing the TruTTM (v2.0) algorithm embedded into electronic medical record (EMR) for wider clinical adoption. These studies will improve clinical care and [U]advance our fundamental understanding of dynamic regulation of T bioavailability[/U] in diverse populations including unrepresented sexual and gender minorities.[/I] Phase IIB: Development of TruT Algorithm for Commercialization in Androgen Disorders (2022) Project Start Date: [I]15 September 2014[/I] Project End Date: [I]31-August-2024[/I] [ATTACH type="full" alt="Screenshot (18628).png"]26983[/ATTACH] [ATTACH type="full" alt="Screenshot (18629).png"]26984[/ATTACH] Phase II: Research and Commercialization of TruT Algorithm for Free Testosterone (2018)[/B] [URL unfurl="true"]https://reporter.nih.gov/search/15ECC90D4A8BC3D57598B8961CAA4A01A2FFCEB861BF/project-details/9564777[/URL] [B]Phase II: Research and Commercialization of TruT Algorithm for Free Testosterone (2017)[/B] [URL unfurl="true"]https://reporter.nih.gov/search/15ECC90D4A8BC3D57598B8961CAA4A01A2FFCEB861BF/project-details/9466689[/URL] [B]Novel Algorithm for Free Testosterone Determination (2014)[/B] [URL unfurl="true"]https://reporter.nih.gov/search/15ECC90D4A8BC3D57598B8961CAA4A01A2FFCEB861BF/project-details/8647313[/URL] [URL unfurl="true"]https://www.sciencedirect.com/science/article/abs/pii/S030372071400272X?via%3Dihub[/URL] [URL unfurl="true"]https://academic.oup.com/edrv/article/38/4/302/3897170[/URL] [URL unfurl="true"]https://www.excelmale.com/forum/threads/allosterically-coupled-multi-site-binding-of-t-to-human-serum-albumin.22102/[/URL] [URL unfurl="true"]https://www.excelmale.com/forum/threads/the-dynamics-of-allosteric-binding-of-estradiol-to-shbg.23268/#post-199558[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Blood Test Discussion
Calculate Free Testosterone with TruT by FPT
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top